Marinomed Biotechnologie has announced that a randomized, double-blind placebo-controlled study of more than 200 patients suffering from the common cold found that patients who received a Carragelose-based nasal spray reduced the duration of symptoms by 2.1 days. Data also showed that patients’ viral load was significantly reduced. The study was published in Respiratory Research on November 13, 2013.
Mariomed CEO and co-founder Andreas Grassauer said,“We are delighted about this evidence derived from such a comprehensive study, confirming the clinical effectiveness of our unique product. The generated results support the marketing of our product portfolio and thus set a further economic milestone for our company. In addition, the data contribute to the development of further therapies in the field of respiratory viral infections.”
The Carragelose excipient is a polymer made from a red algae extract, which the company says “creates a protective layer preventing viruses from entering the nasal mucosa and is the first product effective against a broad spectrum of respiratory viruses worldwide.” Marinomed’s Coldamaris nasal spray was approved as a natural health product in Canada earlier this year and is marketed in 16 countries according to the company.
Read the Marinomed press release.
Read the Respiratory Research article.
